phone Book Now
phone Book Now
Rockyview Health Centre, 1011 Glenmore Trail SW Building #1 Suite 423, Calgary, AB T2V 4R6, Canada
587-353-5061 Book Appointment

CEQUA Drops Advanced Dry Eyes Treatment

Dry Eyes Treatment CEQUA

Introducing CEQUA

CEQUA, a new prescription dry eye solution, was just launched in Canada. CEQUA is one of three prescription drops approved in Canada to treat dry eye disease. What makes CEQUA unique is that it is formulated with Nanomicelle technology, which can form a protective shell around the active ingredient (cyclosporine) and deliver it to where it is needed on the eye’s front surface.

Exciting news for dry eye patients this month! A new dry eye prescription eye drop has launched in Canada called CEQUA (cyclosporine ophthalmic solution) 0.09%

How does CEQUA Work?

In studies, CEQUA has been indicated to increase tear production and reduce inflammation on the eye’s front surface. CEQUA is also simply dosed and has demonstrated an excellent long-term safety and tolerability profile.

5 Key Benefits Of CEQUA You Should Know

  • Tackle inflammation to trigger your tears
  • CEQUA helps you produce more of your own natural tears
  • See signs of improvement within 3 months of using these eyedrops
  • Helpful in Chronic Dry eye condition
  • Easy to use with long-lasting effects.
  • It can be used with ongoing treatments. Talk to your doctor at Eyedeology
  • Trusted brand by most Optometrists

What We Recommend

If you have been using many over-the-counter eye drops or a different dry eye medication and are struggling with your dry eyes

Book an appointment with Eyedeology to see our Calgary Optometrists for a dry eye assessment. We can determine if CEQUA is a good option to help manage your dry eye disease.

 

What is CEQUA and how do I know if it is working for me?

CEQUA (0.09% cyclosporine ophthalmic solution) is a drop used to treat chronic dry eye disease. It helps to increase tear production in just 3 months with improvement in signs in as little as one month. You should notice a reduction in your dry eye signs and symptoms and improved quality of life

How long can I use CEQUA?

Depending on the severity of your dry eyes, CEQUA can be used long-term to treat chronic dry eye disease.

Are there any possible side-effects of CEQUA?

One of the most common side effects of CEQUA is stinging on insertion of the drop and eye redness. Other reported side effects include eye irritation, eyelid inflammation, headache, and urinary tract infection.

Should I consult an Optometrist before using CEQUA?

As CEQUA is a medication, it can only be prescribed and is not available over the counter. We recommend getting a dry eye assessment with our Optometrists at Eyedeology to determine if CEQUA is right for you.

recent post

phone Call NowBook Now

Advanced Myopia Control for Children

Recent randomized controlled clinical trial results presented at the ARVO 2026 Annual Meeting showed promising results for children aged 4–12. Among the 196 children who completed the study, those wearing MiYOSMART iQ showed no average myopia progression after 12 months. The study also found that excessive axial eye growth was reduced to levels below or comparable to those seen in children without refractive errors.

Designed to Help Control Myopia Progression

Myopia, commonly known as short-sightedness, can progress during childhood as the eye grows excessively. Managing myopia earlier in life may help reduce the impact of continued progression and the associated risks of high myopia later in life.

MiYOSMART iQ builds on the established D.I.M.S. Technology used in MiYOSMART lenses and introduces a Triple Enhanced Design (TED). This design incorporates three key enhancements:

  1. Defocus Segments Closer to the Center: The segments are positioned closer to the geometric center of the lens to provide continued exposure to myopic defocus across the near-peripheral retina.
  2. Higher Defocus Power: The lens provides a stronger myopic defocus signal intended to support myopia control.
  3. Extended Treatment Zone: A larger treatment area provides broader coverage of the child’s peripheral visual field, including when larger frames are used.

Clinical Results Across Different Age Groups

The clinical trial included children between 4 and 12 years of age, with results demonstrating myopia-control efficacy across the age groups studied.

For children aged 4–6 years, MiYOSMART iQ demonstrated 65% efficacy in spherical equivalent refractive error (SER) and 44% efficacy in axial length over 12 months. For children aged 7–12 years, the lens demonstrated over 100% efficacy in SER and 94% efficacy in axial length during the same period.

The study also reported a high level of compliance with daily, all-day wear among children across the age groups studied.

Built on Established D.I.M.S. Technology

MiYOSMART iQ represents an evolution of MiYOSMART, a myopia-control lens technology backed by more than 100 peer-reviewed scientific publications. The updated lens design builds on research into how the eye responds to myopic defocus and focuses on delivering a stronger and more consistently positioned defocus signal.

Since its launch in 2018, more than 15 million MiYOSMART spectacle lenses have been purchased by parents across more than 50 countries worldwide.

Supporting Earlier Myopia Management

The clinical findings for MiYOSMART iQ include children as young as four years old, representing an important development in spectacle-lens-based myopia control. Early-onset myopia can progress during a critical period of childhood eye development, making appropriate management an important consideration for children with progressive myopia. MiYOSMART iQ provides an advanced spectacle-lens option for children who require myopia management. An eye care professional can assess your child’s vision and determine whether this type of lens is appropriate for their individual needs.
587-317-2134